pCR, which is defined as the absence of invasive cancer in the breast and lymph nodes after treatment, can be measured within weeks of starting a drug. Thus, it can provide a very early indicator ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

The superior sensitivity of qRT-PCR, [95] with its optimum tissue sampling and capacity for single-cell discrimination, may identify occult cancer cells in lymph nodes below the threshold of ...

Selected patients with a clinical response after therapy could benefit from salvage surgery in non–small cell lung cancer ...

The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...